EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.1602 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jonathan Williams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lundbeck LLC, Deerfield, IL, USA. Hauptthemen laut MEDLINE: Serotonin 5-HT2 Receptor Agonists. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Longboard Pharmaceuticals, Lundbeck, H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT 2C ) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and pharmacokinetic profile of bexicaserin in healthy participants. Doses ranging from 3 to 24 mg three times daily (TID) were administered for up to 14 days. Serial blood and urine samples were collected to assess pharmacokinetics, and prolactin was assessed as a pharmacodynamic biomarker. Bexicaserin was generally safe and well‐tolerated, rapidly absorbed, metabolized to three circulatory pharmacologically inactive metabolites, and had a median T max of about 1–2 h. C max accumulation ranged from 1.5 to 5.1‐fold for all analytes after multiple doses. M20 was the major metabolite, with exposures ranging from 9 to 33‐fold versus bexicaserin. Overall clearance of bexicaserin ranged from 45.9 to 125 L/h, with renal clearance between 5.04 to 6.58 L/h, suggesting that hepatic metabolism and/or excretion is the main elimination pathway. There was a weak dose‐dependent positive correlation between bexicaserin C max and prolactin mean percentage change from baseline, suggesting successful engagement of central 5‐HT 2C receptors. Overall, this Phase 1 MAD study demonstrated bexicaserin to be safe and well‐tolerated, with rapid absorption, presence of one major metabolite, accumulation upon multiple dosing TID, and a greater than dose‐proportional increase in exposures. These findings support the continued development of bexicaserin, which is currently in Phase 3 clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serotonin 5-HT2 Receptor AgonistsHumansDouble-Blind MethodMaleAdultFemaleYoung AdultHealthy VolunteersDose-Response Relationship, DrugMiddle AgedProlactinAdolescent

Stichwörter der Autor:innen

5‐HT2Cbexicaserinepilepsymultiple ascending dosepharmacodynamicspharmacokineticsprolactin

Substanzen

ProlactinSerotonin 5-HT2 Receptor Agonists

Autor:innen und Institutionen

  • Lundbeck LLC, Deerfield, IL, USA.
  • Longboard Pharmaceuticals (now part of Lundbeck LLC), La Jolla, CA, USA.
  • Lundbeck Ltd, Watford, UK.

Förderung

  • Longboard Pharmaceuticals
  • Lundbeck
  • H. Lundbeck A/S

Zitieren

APA

Williams, J., Chan, R., Orevillo, C., O'Connell, G., McLin, D., Polega, S., Srinivas, N. R., & Kaye, R. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1602

Vancouver

Williams J, Chan R, Orevillo C, O'Connell G, McLin D, Polega S, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1602

BibTeX
@article{Williams2026,
  author = {Williams, Jonathan and Chan, Rosa and Orevillo, Chad and O'Connell, Gale and McLin, Dewey and Polega, Shikha and Srinivas, Nuggehally R and Kaye, Randall},
  title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.1602}
}
Kostenlos starten →